News and Media

human trials sakura bead
First Human Trials of SakuraBead Successful – Chronic Knee Pain

All of us at CrannMed were extremely proud to treat our first patients last week. We treated three patients suffering from long-term chronic knee pain.

Read More
CrannMed announced as recipient of Government funding under the Disruptive Technology and Innovation Fund (DTIF)

We are delighted to have been confirmed as one of the companies approved for DTIF grant funding this year. This is awarded to projects…

Read More
shoulder pain
CrannMed obtains second “Breakthrough Device Designation” from the FDA for Adhesive Capsulitis

We are thrilled to announce that the FDA has granted us our second Breakthrough Device Designation. This designation is specifically for the application of our…

Read More
SakuraBead pre-clinical data presented at GEST MSK 2023

We were delighted to have our pre-clinical data on SakuraBead, our resorbable embolization microspheres, presented for the first time at the inaugural GEST MSK 2023…

Read More
Dr Yilun Koethe joins CrannMed Advisory Board

The CrannMed team are delighted to welcome Dr Yilun Koethe to their Advisory Board. Dr Koethe will join existing Board members Dr Ari Isaacson, Dr…

Read More
New Cleanroom Installation

Last month, we finished the installation and validation of our new, class 8 cleanroom. This was the final step in allowing us to build finished,…

Read More
CrannMed moves into new offices – expanding footprint and positioning for growth

CrannMed has expanded into new premises. The company, which formed in 2018, is moving to 6,000 sq ft premises in the Galway Technology Park, Parkmore,…

Read More
CrannMed receives €3.5M from Horizon EIC Accelerator

CrannMed has been awarded €3.5m via the highly competitive EU funded Horizon EIC Accelerator project instrument. This 2-year project will fund a pivotal clinical trial,…

Read More
SakuraBead consortium wins ‘Disruptive Technologies Innovation Fund’ grant

CrannMed along with their consortium partners are proud to announce that they have been awarded €2.5 Million from the Disruptive Technologies Innovation Funding (DTIF) run…

Read More
CrannMed - Knee Osteoarthritis Therapy
CrannMed obtains “Breakthrough Device Designation” from the FDA for its innovative Knee Osteoarthritis therapy

CrannMed has obtained a Breakthrough Device Designation by the U.S Food and Drug Administration for its EmboSure Microspheres used to treat patients suffering from…

Read More